C4X’s interims revealed a refinement of its hybrid business model, whereby it will stop offering access to its drug discovery technology on a fee-for-service basis, instead seeking to strike more strategic and collaborative agreements with pharma/biotech partners. The recent £1.67m acquisition of Adorial, with an innovative technology to help identify novel drug targets, could significantly enhance and accelerate C4X’s drug discovery capabilities. With £5m in cash as of 31 January 2016, and operating costs on the rise to support pipeline and technology development, we anticipate a fresh financing in H216.
29 Mar 2016
A more refined approach


Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
A more refined approach
C4X Discovery Holdings PLC (C4XD:LON) | 38.0 -0.2 (-1.3%) | Mkt Cap: 86.0m
- Published:
29 Mar 2016 -
Author:
Linda Pomeroy -
Pages:
3 -
C4X’s interims revealed a refinement of its hybrid business model, whereby it will stop offering access to its drug discovery technology on a fee-for-service basis, instead seeking to strike more strategic and collaborative agreements with pharma/biotech partners. The recent £1.67m acquisition of Adorial, with an innovative technology to help identify novel drug targets, could significantly enhance and accelerate C4X’s drug discovery capabilities. With £5m in cash as of 31 January 2016, and operating costs on the rise to support pipeline and technology development, we anticipate a fresh financing in H216.